Literature DB >> 30611122

Clinical Outcomes and Cost Comparisons of Stent and Non-Stent Interventions in Infrainguinal Peripheral Artery Disease: Insights From the Excellence in Peripheral Artery Disease (XLPAD) Registry.

Subhash Banerjee1, Haekyung Jeon-Slaughter, Ehrin J Armstrong, Christopher Bajzer, Mazen Abu-Fadel, Houman Khalili, Anand Prasad, Bassel Bou Dargham, Preeti Kamath, Tayo Addo, Michael Luna, Osvaldo Gigliotti, Mazin Foteh, Ian Cawich, Scott Kinlay, Mujtaba Ali, Bala Ramanan, Khusrow Niazi, Shirling Tsai, Nicolas W Shammas, Emmanouil S Brilakis.   

Abstract

BACKGROUND: The contemporary limb outcomes and costs of stent-based vs non-stent based strategies in endovascular revascularization of femoropopliteal (FP) peripheral artery disease (PAD) are not well understood. METHODS AND
RESULTS: We present data from the ongoing United States multicenter Excellence in Peripheral Artery Disease Registry between 2006-2016 to compare stent vs non-stent treatment outcomes and associated costs in FP interventions. A total of 2910 FP interventions were performed in 2162 patients (mean age, 66 years), comprising 1339 stent based (superficial femoral artery, 93%) in 1007 patients and 1571 non-stent interventions (superficial femoral artery, 85%) in 1155 patients. A growing trend for non-stent based interventions and a declining trend in repeat revascularization rate at 1 year were observed across years of registry enrollment. Stent implantation was the prevailing strategy in treating longer FP lesions (mean length, 152 mm vs 105 mm; P<.001) and chronic total occlusions (65% vs 40%; P<.001), while stent implantation was employed less frequently when treating in-stent restenotic lesions (14% vs 20%; P<.001). Stent and non-stent interventions had similar 1-year limb outcomes in all-cause death, target-limb revascularization, target-vessel revascularization, and major or minor amputation. The average procedure costs for the stent group were significantly higher than the non-stent group ($6215 vs $4790; P<.001).
CONCLUSION: There is a growing trend for non-stent FP artery interventions, with a significant decline in 1-year target-limb revascularization rates over time. One-year limb outcomes in stent-based compared to non-stent interventions are similar; however, at a significantly higher procedural cost.

Entities:  

Keywords:  chronic total occlusions; superficial femoral artery

Mesh:

Year:  2019        PMID: 30611122      PMCID: PMC6428413     

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  21 in total

1.  Stent and Non-Stent Based Outcomes of Infrainguinal Peripheral Artery Interventions From the Multicenter XLPAD Registry.

Authors:  Subhash Banerjee; Gene Pershwitz; Karan Sarode; Atif Mohammad; Mazen S Abu-Fadel; Mirza S Baig; Shirling Tsai; Bertis B Little; Osvaldo S Gigliotti; Ediberto Soto-Cora; Mazin I Foteh; Gerardo Rodriguez; Andrew Klein; Tayo Addo; Michael Luna; Nicolas W Shammas; Anand Prasad; Emmanouil S Brilakis
Journal:  J Invasive Cardiol       Date:  2015-01       Impact factor: 2.022

2.  Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH).

Authors:  Ilka Ott; Salvatore Cassese; Philipp Groha; Birgit Steppich; Martin Hadamitzky; Tareq Ibrahim; Sebastian Kufner; Karl Dewitz; Regina Hiendlmayer; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati; Massimiliano Fusaro
Journal:  Circulation       Date:  2017-04-19       Impact factor: 29.690

3.  Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease.

Authors:  Michael R Jaff; Kevin E Cahill; Andrew P Yu; Howard G Birnbaum; Luella M Engelhart
Journal:  Ann Vasc Surg       Date:  2010-07       Impact factor: 1.466

4.  Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010.

Authors:  Heather Franklin; Mangala Rajan; Chin-Lin Tseng; Len Pogach; Anushua Sinha; Md Mph
Journal:  J Rehabil Res Dev       Date:  2014

Review 5.  Endovascular Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of Current Technologies.

Authors:  Michael R Jaff; Teresa Nelson; Nicole Ferko; Melissa Martinson; Louise H Anderson; Sarah Hollmann
Journal:  J Vasc Interv Radiol       Date:  2017-10-12       Impact factor: 3.464

6.  Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.

Authors:  Marc P Bonaca; Mark A Creager; Jeffrey Olin; Benjamin M Scirica; Ian C Gilchrist; Sabina A Murphy; Erica L Goodrich; Eugene Braunwald; David A Morrow
Journal:  JACC Cardiovasc Interv       Date:  2016-10-24       Impact factor: 11.195

7.  Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease.

Authors:  Andrew J Meltzer; Art Sedrakyan; Peter H Connolly; Sharif Ellozy; Darren B Schneider
Journal:  Ann Vasc Surg       Date:  2017-06-08       Impact factor: 1.466

8.  Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions.

Authors:  Sanne W de Boer; Daniel A F van den Heuvel; Debbie A B de Vries-Werson; Jan Albert Vos; Bram Fioole; Damnis Vroegindeweij; Otto E Elgersma; Rudolph P Tutein Nolthenius; Jan M M Heyligers; Gerlof P T Bosma; Bernart de Leeuw; Lee H Bouwman; Dittmar Böckler; Dmitriy I Dovzhanskiy; Floris W F Vos; Ted W F Vink; Pieter G A Hooijboer; Rutger J Hissink; Jean-Paul P M de Vries
Journal:  J Endovasc Ther       Date:  2017-08-10       Impact factor: 3.487

9.  Endovascular Versus Open Revascularization for Peripheral Arterial Disease.

Authors:  Jason T Wiseman; Sara Fernandes-Taylor; Sandeep Saha; Jeffrey Havlena; Paul J Rathouz; Maureen A Smith; K Craig Kent
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

10.  Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.

Authors:  Thomas Zeller; Ralf Langhoff; Krishna J Rocha-Singh; Michael R Jaff; Erwin Blessing; Beatrice Amann-Vesti; Marek Krzanowski; Patrick Peeters; Dierk Scheinert; Giovanni Torsello; Sebastian Sixt; Gunnar Tepe
Journal:  Circ Cardiovasc Interv       Date:  2017-09       Impact factor: 6.546

View more
  3 in total

Review 1.  [Innovations in the endovascular treatment of peripheral arterial disease].

Authors:  Jörg Teßarek; Alexander Oberhuber
Journal:  Gefasschirurgie       Date:  2021-08-13

2.  Jetstream Atherectomy Followed by Paclitaxel-Coated Balloons versus Balloon Angioplasty Followed by Paclitaxel-Coated Balloons: Twelve-Month Exploratory Results of the Prospective Randomized JET-RANGER Study.

Authors:  Nicolas W Shammas; Bhaskar Purushottam; W John Shammas; Lori Christensen; Gail Shammas; Desyree Weakley; Sue Jones-Miller
Journal:  Vasc Health Risk Manag       Date:  2022-08-02

Review 3.  Applying Principles of Regenerative Medicine to Vascular Stent Development.

Authors:  Prakash Parthiban Selvakumar; Michael Scott Rafuse; Richard Johnson; Wei Tan
Journal:  Front Bioeng Biotechnol       Date:  2022-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.